|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||
| Current assets: | |||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||
| Marketable securities | |||||||||||||||||
| Accounts receivable, net | |||||||||||||||||
| Inventory | |||||||||||||||||
| Prepaid expenses and other current assets | |||||||||||||||||
| Research and development tax credit receivable | |||||||||||||||||
| Total current assets | |||||||||||||||||
| Non-current assets: | |||||||||||||||||
| Operating lease right-of-use-assets | |||||||||||||||||
| Property and equipment, net | |||||||||||||||||
| Research and development tax credit receivable | |||||||||||||||||
| Restricted cash | |||||||||||||||||
| Intangible assets, net | |||||||||||||||||
| Other assets | |||||||||||||||||
| Total non-current assets | |||||||||||||||||
| Total assets | |||||||||||||||||
| Liabilities and Shareholders' Equity | |||||||||||||||||
| Current liabilities: | |||||||||||||||||
| Accounts payable | |||||||||||||||||
| Accrued expenses and other current liabilities | |||||||||||||||||
| Deferred revenue | |||||||||||||||||
| Operating lease liabilities | |||||||||||||||||
| Notes payable | |||||||||||||||||
| Total current liabilities | |||||||||||||||||
| Notes payable, long-term | |||||||||||||||||
| Deferred revenue, net of current portion | |||||||||||||||||
| Operating lease liabilities, net of current portion | |||||||||||||||||
| PIPE Warrant and PIPE unit liabilities | |||||||||||||||||
| PIPE Warrant liabilities | |||||||||||||||||
| Other long-term liabilities | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| Shareholders’ equity: | |||||||||||||||||
| Ordinary shares (voting and non-voting), GBP 0.10 par value; Most recent authority to allot up to a maximum nominal value of GBP 33,556,809 and GBP 13,023,851.50 of shares at September 30, 2023 and December 31, 2022, respectively; Issued and outstanding - 227,273,209 and 126,947,225 ordinary shares at September 30, 2023 and December 31, 2022, respectively. | |||||||||||||||||
| Additional paid-in capital | |||||||||||||||||
| Accumulated other comprehensive income | |||||||||||||||||
| Accumulated deficit | |||||||||||||||||
| Total shareholders’ equity | |||||||||||||||||
| Total liabilities and shareholders’ equity | |||||||||||||||||
Loading...
